Zydus Cadila has received the final approval from the USFDA for Mesalamine Delayed-Release Tablets in the strength of 800 mg. The drug will be manufactured at the group's formulation manufacturing facility at Moraiya.
The group has received 27 final ANDA approvals from the USFDA and 2 tentative ANDA approvals since January 2017. The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.544.3 as compared to the previous close of Rs. 531.65. The total number of shares traded during the day was 211567 in over 4277 trades.
The stock hit an intraday high of Rs. 554.2 and intraday low of 531.1. The net turnover during the day was Rs. 115167485.
Source: Zydus receives final approval from USFDA for Mesalamine Delayed -Release Tablets, 800 mg
No comments:
Post a Comment